StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
603313.SS$5.63+1.40%
Fair $5.63+0.0%

603313.SS

Healthcare Co.,Ltd.

Consumer Cyclical / Furnishings, Fixtures & AppliancesShanghai

$5.63

+0.08 (+1.40%)

Fairly Valued+0.0%Fair Value $5.63Fund rank 25/100 · Data gapFallback financials|
SA 18/F
F-Score: 6/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 32% · confianza 23%

FCF escenarios

weak_data · normalized FCF $502.1M · quality 46.3/100

Data gap 25/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 32/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

18/100

F

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -0.3%, below the 5% threshold
Thesis & Journal · 603313.SSLocal privado en este navegador · Healthcare Co.,Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$3.2B

P/E

N/A

•

EV/EBITDA

7.3x

↓

ROE

-0.3%

↓

Gross Margin

39.3%

↑

Debt/Equity

1.09

↑
52-Week Range$6
$6$11

TradingView lightweight chart

603313.SS price, volumen y niveles de valoración

Último $5.780Periodo -56.0%
Fair value: $5.630

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+3.6%

FCF CAGR

—

FCF margin

5.6%

FCF / Net income

-50.58x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $8.91B · net income $-9.8M · FCF $496.8M

2022-FY → 2025-FY

Gross margin

39.3%+8.2% pts

Operating margin

4.8%+0.9% pts

Net margin

-0.1%-0.6% pts

FCF margin

5.6%+6.4% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$8.91B$8.91B$8.45B$7.98B$8.02B
Net Income$-9.8M$-9.8M$-151.4M$106.6M$41.4M
EBITDA$754.9M$754.9M$575.0M$884.2M$707.8M
EPS-0.02-0.02-0.270.220.09
Gross Margin39.3%39.3%36.9%38.4%31.0%
Operating Margin4.8%4.8%4.9%7.6%3.8%
Net Margin-0.1%-0.1%-1.8%1.3%0.5%
Balance Sheet
Debt/Equity1.091.091.041.041.36
Current Ratio1.031.03———
Cash Flow
Free Cash Flow$496.8M$496.8M$584.6M$502.1M$-65.7M
Returns
ROE-0.3%-0.3%-4.2%2.7%1.4%
Valuation
P/E———50.73123.11
EV/EBITDA7.297.2911.329.4512.14
P/B0.790.791.031.391.71
Growth & Yield
Revenue Growth5.5%5.5%5.9%-0.5%—
EPS Growth92.6%92.6%-222.7%144.4%—
Dividend Yield0.5%0.5%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -29.2%

Total return

-29.2%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.27 → -0.02

Residual

-29.7%

EPS growthn/d
Multiple reratingn/d
Dividend+0.5%
Residual / FX / buybacks / cross-term-29.7%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.